Che‐Kai Tsao

2.8k total citations
80 papers, 769 citations indexed

About

Che‐Kai Tsao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Che‐Kai Tsao has authored 80 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 23 papers in Cancer Research. Recurrent topics in Che‐Kai Tsao's work include Prostate Cancer Treatment and Research (38 papers), Bladder and Urothelial Cancer Treatments (15 papers) and Renal cell carcinoma treatment (14 papers). Che‐Kai Tsao is often cited by papers focused on Prostate Cancer Treatment and Research (38 papers), Bladder and Urothelial Cancer Treatments (15 papers) and Renal cell carcinoma treatment (14 papers). Che‐Kai Tsao collaborates with scholars based in United States, India and Germany. Che‐Kai Tsao's co-authors include William Oh, Matthew D. Galsky, John P. Sfakianos, Alexander Small, Erin Moshier, Kristian Stensland, Paolo Boffetta, Madhu Mazumdar, James Godbold and Russell B. McBride and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Che‐Kai Tsao

73 papers receiving 760 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Che‐Kai Tsao United States 15 356 260 253 158 122 80 769
Jae Young Joung South Korea 17 446 1.3× 160 0.6× 195 0.8× 211 1.3× 155 1.3× 82 818
Spyridon P. Basourakos United States 14 317 0.9× 164 0.6× 121 0.5× 171 1.1× 120 1.0× 67 652
Peter Hammerer Germany 15 478 1.3× 176 0.7× 155 0.6× 190 1.2× 108 0.9× 52 868
Friedemann Zengerling Germany 16 339 1.0× 205 0.8× 369 1.5× 207 1.3× 85 0.7× 102 777
Matthew R. Zibelman United States 19 367 1.0× 455 1.8× 315 1.2× 276 1.7× 130 1.1× 85 954
Tatsuo Tochigi Japan 21 708 2.0× 175 0.7× 188 0.7× 175 1.1× 124 1.0× 61 999
Takashi Fukagai Japan 14 477 1.3× 187 0.7× 138 0.5× 81 0.5× 116 1.0× 67 727
Alan Paul United Kingdom 17 265 0.7× 156 0.6× 267 1.1× 407 2.6× 113 0.9× 29 857
Kenneth R. Blank United States 10 669 1.9× 174 0.7× 200 0.8× 155 1.0× 109 0.9× 18 967
S. Melchior Germany 11 380 1.1× 149 0.6× 139 0.5× 336 2.1× 136 1.1× 34 672

Countries citing papers authored by Che‐Kai Tsao

Since Specialization
Citations

This map shows the geographic impact of Che‐Kai Tsao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Che‐Kai Tsao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Che‐Kai Tsao more than expected).

Fields of papers citing papers by Che‐Kai Tsao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Che‐Kai Tsao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Che‐Kai Tsao. The network helps show where Che‐Kai Tsao may publish in the future.

Co-authorship network of co-authors of Che‐Kai Tsao

This figure shows the co-authorship network connecting the top 25 collaborators of Che‐Kai Tsao. A scholar is included among the top collaborators of Che‐Kai Tsao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Che‐Kai Tsao. Che‐Kai Tsao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galsky, Matthew D., Che‐Kai Tsao, Kyrollis Attalla, et al.. (2025). Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancer. British Journal of Urology. 136(6). 1098–1106. 1 indexed citations
2.
3.
Patel, Vaibhav G., Deepak Kumar Singh, Himanshu Joshi, et al.. (2024). Abstract CT223: Dormancy reprograming therapy of 5-azacitidine (AZA) and all-trans retinoic acid (ATRA) in biochemically recurrent prostate cancer. Cancer Research. 84(7_Supplement). CT223–CT223. 2 indexed citations
4.
Joshi, Himanshu, et al.. (2024). Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. Clinical Genitourinary Cancer. 22(3). 102066–102066. 6 indexed citations
5.
6.
Chen, Tzu-Yi, Reza Mehrazin, Che‐Kai Tsao, et al.. (2023). Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer. International Journal of Molecular Sciences. 24(19). 14713–14713. 6 indexed citations
7.
Qin, Qian, Tomi Jun, Bo Wang, et al.. (2022). Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis. Discover Oncology. 13(1). 73–73. 6 indexed citations
8.
Patel, Vaibhav G., Xiaobo Zhong, Himanshu Joshi, et al.. (2022). Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal of Cancer Research and Clinical Oncology. 149(7). 2833–2841. 15 indexed citations
9.
Izadmehr, Sudeh, Dara Lundon, Nihal Mohamed, et al.. (2021). The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. Frontiers in Oncology. 11. 734963–734963. 4 indexed citations
10.
Qin, Qian, Xiaobo Zhong, Justin Lin, et al.. (2021). Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?. Clinical Genitourinary Cancer. 19(6). e346–e351. 1 indexed citations
11.
Lundon, Dara, Johnathan A. Khusid, Che‐Kai Tsao, et al.. (2021). COVID-19 vaccination: Prioritization of at risk groups. Urologic Oncology Seminars and Original Investigations. 39(7). 375–378. 1 indexed citations
12.
Smith, Cardinale B., et al.. (2020). Impact of Pharmacist-Led Patient Education in an Ambulatory Cancer Center: A Pilot Quality Improvement Project. Journal of Pharmacy Practice. 35(2). 268–273. 8 indexed citations
13.
Dovey, Zachary, Kennedy E. Okhawere, Nihal Mohamed, et al.. (2020). Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer. Cancers. 12(9). 2442–2442. 7 indexed citations
14.
Mehrazin, Reza, et al.. (2017). Management of Atypical Renal Cell Carcinomas. Current Treatment Options in Oncology. 18(10). 61–61. 2 indexed citations
15.
Wang, Li, Yixuan Gong, Matthias Heck, et al.. (2015). A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Medicine. 13(1). 201–201. 15 indexed citations
16.
Galsky, Matthew D., Marshall R. Posner, Randall F. Holcombe, et al.. (2014). Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 74(3). 465–471. 13 indexed citations
17.
Tsao, Che‐Kai, et al.. (2013). Metabolic and toxicological considerations of newly approved prostate cancer drugs. Expert Opinion on Drug Metabolism & Toxicology. 9(7). 835–846. 3 indexed citations
18.
Galsky, Matthew D., Alexander Small, Che‐Kai Tsao, & William Oh. (2012). Clinical development of novel therapeutics for castration‐resistant prostate cancer. CA A Cancer Journal for Clinicians. 62(5). 299–308. 34 indexed citations
19.
Tsao, Che‐Kai, Erin Moshier, James Godbold, et al.. (2011). Impact of the CKD-EPI Equation for Estimating Renal Function on Eligibility for Cisplatin-based Chemotherapy in Patients With Urothelial Cancer. Clinical Genitourinary Cancer. 10(1). 15–20. 31 indexed citations
20.
Tsao, Che‐Kai, et al.. (2011). Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer. Clinical Medicine Insights Oncology. 5. 163–9. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jae Young Joung Breakdown of academic impact, for papers by Spyridon P. Basourakos Breakdown of academic impact, for papers by Peter Hammerer Breakdown of academic impact, for papers by Friedemann Zengerling Breakdown of academic impact, for papers by Matthew R. Zibelman Breakdown of academic impact, for papers by Tatsuo Tochigi Breakdown of academic impact, for papers by Takashi Fukagai Breakdown of academic impact, for papers by Alan Paul Breakdown of academic impact, for papers by Kenneth R. Blank Breakdown of academic impact, for papers by S. Melchior
Rankless by CCL
2026